Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegpleranib + anti-VEGF therapy
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
Pegpleranib + anti-VEGF therapy is a **combination treatment** investigated for neovascular (wet) age-related macular degeneration (AMD). Pegpleranib (code name Fovista) is an aptamer that targets platelet-derived growth factor subunit B (PDGF-B), stripping pericytes from abnormal neovascular vessels, thereby making them more susceptible to anti-VEGF therapy, which targets the vascular endothelial growth factor pathway responsible for angiogenesis. The anti-VEGF agent used in combination has commonly been ranibizumab, aflibercept, or bevacizumab. This dual approach aims to maximize vessel regression and visual outcomes compared to anti-VEGF monotherapy, though Phase 3 trials did not meet their prespecified primary efficacy endpoints.
- Other names
- pegpleranib + anti-VEGFpegpleranib plus anti-VEGF therapypegpleranib + ranibizumabpegpleranib + afliberceptpegpleranib + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)PDGFB (PDGF-B)
Beyond the preview
Go deeper on pegpleranib + anti-VEGF therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegpleranib + anti-VEGF therapy.